Literature DB >> 16408099

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.

J-J Kiladjian1, E Bourgeois, I Lobe, T Braun, G Visentin, J-H Bourhis, P Fenaux, S Chouaib, A Caignard.   

Abstract

Natural Killer (NK) cells are critical in host defense against malignant transformation and are potent antileukemic cytotoxic effectors. In the present study, we investigated the peripheral NK function in patients with myelodysplastic syndromes (MDS). We demonstrated that the peripheral NK cell population was quantitatively normal in MDS patients. Furthermore, NK cells displayed an expression of the activating natural cytotoxicity receptors (NCR) NKp46 and NKp30 as well as NKG2D similar to that observed in donors, but exert a highly decreased constitutive cytolytic activity compared to resting normal NK cells. Although activation with IL-2 resulted in the upregulation of NKp46 expression by MDS-NK cells, their cytolytic function remained deeply altered as compared to activated donor NK cells. In addition, MDS NK cells did not proliferate in vitro, and displayed an increased rate of apoptosis in response to IL-2 stimulation although the spontaneous apoptosis was not significantly increased. Interestingly, a proportion of peripheral MDS-NK cells were derived from the MDS clone as the cytogenetic anomaly found in bone marrow karyotype was also detected in 20-50% of circulating NK cells. In conclusion, NK cells' cytolytic function and proliferative capacities in response to activation by cytokines are profoundly altered in MDS.

Entities:  

Mesh:

Year:  2006        PMID: 16408099     DOI: 10.1038/sj.leu.2404080

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

2.  Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.

Authors:  Martin Jädersten
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

3.  Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Authors:  Maryam Hejazi; Angela R Manser; Julia Fröbel; Andrea Kündgen; Xiaoyi Zhao; Kathrin Schönberg; Ulrich Germing; Rainer Haas; Norbert Gattermann; Markus Uhrberg
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 4.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

5.  Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.

Authors:  G Venton; Y Labiad; J Colle; A Fino; S Afridi; M Torres; S Monteuil; B Loriod; N Fernandez-Nunez; L Farnault; P Suchon; J C Mattei; P Rihet; A Bergon; C Nguyen; C Baier; R Costello
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

6.  Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

Authors:  G Kerdivel; V Chesnais; E Becht; A Toma; N Cagnard; F Dumont; A Rousseau; P Fenaux; S Chevret; N Chapuis; V Boeva; W H Fridman; M Fontenay; O Kosmider
Journal:  Leukemia       Date:  2017-10-03       Impact factor: 11.528

7.  A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.

Authors:  Chi-Yuan Yao; Ching-Hsuan Chen; Huai-Hsuan Huang; Hsin-An Hou; Chien-Chin Lin; Mei-Hsuan Tseng; Chein-Jun Kao; Tzu-Pin Lu; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Adv       Date:  2017-08-16

Review 8.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

9.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

10.  Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.

Authors:  A Mario Marcondes; Andrew J Mhyre; Derek L Stirewalt; Soo-Hyun Kim; Charles A Dinarello; H Joachim Deeg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.